Insights

Gathering insights about iMedica…

Similar companies to iMedica

iMedica Tech Stack

iMedica uses 8 technology products and services including Google Ads, DB2, Oracle, and more. Explore iMedica's tech stack below.

Google Ads
Advertising
DB2
Database
Oracle
Enterprise
OneDrive
File Sharing
Windows Server 2016
IT Infrastructure
JSON
Programming Languages
.NET
Programming Languages
SAP Analytics Cloud
Software As A Service

Media & News

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis
CalciMedica, Inc. (NASDAQ: CALC) shares are down on Wednesday after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial.
Jan 28, 2026 | www.benzinga.com
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), a population characterized by high mortality and a lack of approved therapies.
Jan 28, 2026 | www.prnewswire.com
Airbus Clinches Contract to Supply 30 A320neo Aircraft to CALC
EADSY lands a firm order for 30 A320neo aircraft from CALC, reinforcing strong global demand for its fuel-efficient single-aisle aircraft.
Dec 31, 2025 | www.zacks.com
CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell?
CalciMedica Inc. (NASDAQ: CALC - Get Free Report) traded down 2.1% during trading on Tuesday. The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day trading, a decline of 51% from the average session volume of 92,307 shares. The stock had previously closed at $5.85. Wall Street
Dec 31, 2025 | www.defenseworld.net
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026 Cash position expected to fund operations into 2H 2026 LA JOLLA, Calif. , Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2025 and provided clinical and corporate updates.
Nov 12, 2025 | www.prnewswire.com
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing treatments Cardiac benefit supports the mechanistic rationale for CRAC channel inhibition in acute kidney injury (AKI), being evaluated in the Phase 2 KOURAGE trial with data expected in 1H 2026 LA JOLLA, Calif. , Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in JCI (Journal of Clinical Investigation) Insight of data from a preclinical study investigating one of its proprietary drug candidates, CM5480, as a potential new therapy for pulmonary arterial hypertension (PAH).
Nov 12, 2025 | www.prnewswire.com
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of AKI Findings reinforce the mechanistic rationale for Auxora as a potential treatment for severe AKI with respiratory failure, currently being evaluated in the Phase 2 KOURAGE trial LA JOLLA, Calif. , Nov. 10, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a poster presentation titled, "Store-Operated Calcium-Channel Inhibitor Auxora Improves Kidney Function Following Ischemia-Induced AKI in Rats" at the American Society of Nephrology (ASN) Kidney Week 2025.
Nov 10, 2025 | www.prnewswire.com

iMedica's Email Address Formats

iMedica uses at least 2 format(s):

iMedica Email Formats	Example	Percentage
FLast@aprima.com	JDoe@aprima.com	83%
Last@aprima.com	Doe@aprima.com	7%
First_Last@aprima.com	John_Doe@aprima.com	4%
Last_First@aprima.com	Doe_John@aprima.com	2%
FirLast@aprima.com	JohDoe@aprima.com	1%
LastFirst@aprima.com	DoeJohn@aprima.com	1%
LastF@aprima.com	DoeJ@aprima.com	1%
First.Last@aprima.com	John.Doe@aprima.com	1%
First.Last@cgm.com	John.Doe@cgm.com	98%
FirstLast@cgm.com	JohnDoe@cgm.com	2%

Frequently Asked Questions

Where is iMedica's headquarters located?

iMedica's main headquarters is located at United States. The company has employees across 3 continents, including North AmericaEuropeSouth America.

What is iMedica's phone number?

You can contact iMedica's main corporate office by phone at

+1-214-466-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is iMedica's stock symbol?

iMedica is a publicly traded company; the company's stock symbol is CALC.

What is iMedica's official website and social media links?

iMedica's official website is cgm.com and has social profiles on LinkedIn.

What is iMedica's SIC code NAICS code?

iMedica's SIC code is 7372 - Prepackaged Software NAICS code is 5112 - Software Publishers.

How many employees does iMedica have currently?

As of February 2026, iMedica has approximately 41 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include Chief Medical Officer: J. H.Qa Engineer: Y. B.It Responsible: M. B.. Explore iMedica's employee directory with LeadIQ.

What industry does iMedica belong to?

iMedica operates in the Software Development industry.

What technology does iMedica use?

iMedica's tech stack includes Google AdsDB2OracleOneDriveWindows Server 2016JSON.NETSAP Analytics Cloud.

What is iMedica's email format?

iMedica's email format typically follows the pattern of FLast@aprima.com. Find more iMedica email formats with LeadIQ.

iMedica

Q: What is iMedica's official website and social media links?

iMedica's official website is cgm.com. iMedica has social profiles on LinkedIn.

Q: How many employees does iMedica have currently?

iMedica has approximately 41 employees.

Q: What technology does iMedica use?

iMedica's tech stack includes Linux, SAP Analytics Cloud, Methode, Redis, HTML5.

Software DevelopmentUnited States11-50 Employees

CGM APRIMA EHR and practice management system offers a single application to increase your practice’s efficiency. The flexibility of being able to set the system up to work for each provider will simplify workflows without hindering the ability to treat patients. CGM APRIMA EHR learns a provider’s workflow and anticipates treatment plans.